Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
Alessandra Tedeschi, Constantine S Tam, Roger G Owen, Christian Buske, Véronique Leblond, Meletios Dimopoulos, Ramón Garcia-Sanz, Jorge J Castillo, Judith Trotman, Steven P Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Y Chan, Aileen Cohen, Shengnan Chen, Gisoo Barnes
Future Oncol 20(25) 1789-1798
摘要
摘要
Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM).Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and EQ-5D-5L VAS scores.Results: Overall, 201 patients (102 zanubrutinib; 99 ibrutinib) were enrolled. Clinically meaningful differences were observed in diarrhea and nausea/vomiting in both the intent-to-treat population and in patients attaining very good partial response (VGPR) in earlier cycles of treatment, as well as in long-term physical functioning and fatigue in patients achieving VGPR.Conclusion: Treatment with zanubrutinib was associated with greater improvements in health-related quality of life compared with ibrutinib in patients with WM and MYD88 mutations.Clinical Trial Registration: NCT03053440 (ClinicalTrials.gov).
KM 提取结果
0 个 Figure · 0 个 KM 面板